Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.53 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.53 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.53 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.53 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.53 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | S100A4 | P26447 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 2/20 | 0.53 |
| ▸ | TDP2 | O95551 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28596065 | 1.00 | MEN1 (0.53) | MEN1KMT2AMAPK1NPC1MAOA | |
| Hydrochloric Acid SCHEMBL29020358 | 0.95 | MEN1 (0.57) | MEN1KMT2AMAPK1NPC1MAOA | |
| Hydrochloric Acid SCHEMBL31484610 | 0.95 | MEN1 (0.57) | MEN1KMT2AMAPK1NPC1MAOA | |
| Iodide SCHEMBL219547 | 0.95 | MEN1 (0.57) | MEN1KMT2AMAPK1NPC1MAOA | |
| Hydrochloric Acid SCHEMBL4323975 | 0.95 | MEN1 (0.57) | MEN1KMT2AMAPK1NPC1MAOA | |
| Iodide SCHEMBL19583256 | 0.90 | MEN1 (0.53) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL11875421 | 0.89 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL4368339 | 0.89 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL29543474 | 0.89 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL49870 | 0.89 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114916501-B | Application of diphenylene iodonium chloride in model molding of rheumatoid arthritis and model molding method of rheumatoid arthritis | 四川大学华西医院 | 2023-01-31 | — | — | CN | claimed |
| CN-115645369-A | Lung accurate targeting liposome nanoparticle compound and preparation method and application thereof | 山东大学 | 2023-01-31 | — | — | CN | claimed |
| CN-114916501-A | Application of diphenylene iodonium chloride in model molding of rheumatoid arthritis and model molding method of rheumatoid arthritis | 四川大学华西医院 | 2022-08-19 | — | — | CN | claimed |
| CN-111051380-A | Polycycloolefinic polymer as optical material and inorganic nanoparticle composition | 普罗米鲁斯有限责任公司 | 2020-04-21 | — | — | CN | claimed |
| US-20090202439-A1 | Methods for treatment of angiogenesis | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-13 | — | — | US | claimed |
| EP-1799258-A4 | METHODS FOR TREATMENT OF ANGIOGENESIS | UNIV JOHNS HOPKINS (US) | 2009-07-22 | — | — | EP | claimed |
| EP-1799258-A2 | METHODS FOR TREATMENT OF ANGIOGENESIS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006023827-A2 | METHODS FOR TREATMENT OF ANGIOGENESIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-03-02 | — | — | WO | claimed |
| US-20040259942-A1 | Modulation of stat activity | SHAW PETER (GB) | 2004-12-23 | — | — | US | claimed |
| EP-1427406-A2 | MODULATION OF STAT ACTIVITY | University of Nottingham (GB) | 2004-06-16 | — | — | EP | claimed |
| WO-2003026641-A2 | MODULATION OF STAT ACTIVITY | UNIVERSITY OF NOTTINGHAM (GB) | 2003-04-03 | — | — | WO | claimed |
| CN-114916501-B | Application of diphenylene iodonium chloride in model molding of rheumatoid arthritis and model molding method of rheumatoid arthritis | 四川大学华西医院 | 2023-01-31 | — | — | CN | disclosed |
| CN-114916501-B | Application of diphenylene iodonium chloride in model molding of rheumatoid arthritis and model molding method of rheumatoid arthritis | 四川大学华西医院 | 2023-01-31 | — | — | CN | disclosed |
| CN-115645369-A | Lung accurate targeting liposome nanoparticle compound and preparation method and application thereof | 山东大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-115645369-A | Lung accurate targeting liposome nanoparticle compound and preparation method and application thereof | 山东大学 | 2023-01-31 | — | — | CN | disclosed |
| EP-1282411-A1 | METHOD OF TREATING CANCER | Charlotte-Mecklenburg Hospital Authority doing business as Carolinas Medical Center (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-1187910-A1 | METHODS FOR ENHANCING PLANT DEFENSE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001080849-A1 | METHOD OF TREATING CANCER | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1078987-A1 | METHOD FOR EXAMINING CENTRAL NERVOUS SYSTEM DISEASES AND METHOD FOR SCREENING REMEDIES | TANABE SEIYAKU CO., LTD. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000063347-A1 | METHODS FOR ENHANCING PLANT DEFENSE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202439-A1 | Methods for treatment of angiogenesis | B4GALT1, FLT1, FLT4 | MAOA 703/4885S1PR4 244/4885BCHE 1147/4885 |
| US-20040259942-A1 | Modulation of stat activity | STAT3, STAT1, STAT4 | MAOA 4533/4885S1PR4 1633/4885BCHE 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.